JP2024028756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024028756A5 JP2024028756A5 JP2023199561A JP2023199561A JP2024028756A5 JP 2024028756 A5 JP2024028756 A5 JP 2024028756A5 JP 2023199561 A JP2023199561 A JP 2023199561A JP 2023199561 A JP2023199561 A JP 2023199561A JP 2024028756 A5 JP2024028756 A5 JP 2024028756A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant protein
- domain
- dosage unit
- antibody
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 23
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 23
- 102000013462 Interleukin-12 Human genes 0.000 claims 13
- 108010065805 Interleukin-12 Proteins 0.000 claims 13
- 229940117681 interleukin-12 Drugs 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 102000016359 Fibronectins Human genes 0.000 claims 6
- 108010067306 Fibronectins Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 3
- 238000002591 computed tomography Methods 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 230000005746 immune checkpoint blockade Effects 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims 1
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 208000032818 Microsatellite Instability Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 230000033607 mismatch repair Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 238000009121 systemic therapy Methods 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000023747 urothelial carcinoma Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20169469 | 2020-04-14 | ||
| EP20169469.2 | 2020-04-14 | ||
| PCT/EP2021/059570 WO2021209452A1 (en) | 2020-04-14 | 2021-04-13 | Dosage units and regimen, uses, methods or formulations of compositions comprising a recombinant protein comprising interleukin-12 and an antibody binding the extra-domain b of fibronectin |
| JP2022561419A JP7438396B2 (ja) | 2020-04-14 | 2021-04-13 | インターロイキン－１２とフィブロネクチンのエクストラドメインｂに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022561419A Division JP7438396B2 (ja) | 2020-04-14 | 2021-04-13 | インターロイキン－１２とフィブロネクチンのエクストラドメインｂに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024028756A JP2024028756A (ja) | 2024-03-05 |
| JP2024028756A5 true JP2024028756A5 (https=) | 2024-04-18 |
Family
ID=70289595
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022561419A Active JP7438396B2 (ja) | 2020-04-14 | 2021-04-13 | インターロイキン－１２とフィブロネクチンのエクストラドメインｂに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤 |
| JP2023199561A Pending JP2024028756A (ja) | 2020-04-14 | 2023-11-27 | インターロイキン－１２とフィブロネクチンのエクストラドメインｂに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022561419A Active JP7438396B2 (ja) | 2020-04-14 | 2021-04-13 | インターロイキン－１２とフィブロネクチンのエクストラドメインｂに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230312726A1 (https=) |
| EP (1) | EP4135751B1 (https=) |
| JP (2) | JP7438396B2 (https=) |
| AU (1) | AU2021257594B2 (https=) |
| WO (1) | WO2021209452A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023206004B2 (en) * | 2022-01-04 | 2025-04-17 | Philogen S.P.A. | Combination of an immunocytokine comprising il-12 and a kinase inhibitor |
| WO2025061801A1 (en) | 2023-09-19 | 2025-03-27 | Philochem Ag | Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE459648T1 (de) * | 2005-05-11 | 2010-03-15 | Philogen Spa | Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12 |
| EA200802289A1 (ru) | 2006-05-08 | 2009-04-28 | Филоджен Спа | Направляемые к мишени антителами цитокины для терапии |
| GB201612317D0 (en) | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
| EP3749370B1 (de) | 2018-02-07 | 2025-05-07 | Smawa GmbH | Pharmazeutische formulierungen, verfahren zum herstellen einer pharmazeutischen formulierung sowie ein arzneimittel umfassend eine solche |
| TWI844524B (zh) * | 2018-02-09 | 2024-06-11 | 義大利商費洛根公司 | 靶向edb之il-12組合物 |
| EP3781192A1 (en) | 2018-04-16 | 2021-02-24 | Merck Patent GmbH | Additives for protein formulations to improve thermal stability |
-
2021
- 2021-04-13 US US17/996,114 patent/US20230312726A1/en not_active Abandoned
- 2021-04-13 WO PCT/EP2021/059570 patent/WO2021209452A1/en not_active Ceased
- 2021-04-13 EP EP21728830.7A patent/EP4135751B1/en active Active
- 2021-04-13 JP JP2022561419A patent/JP7438396B2/ja active Active
- 2021-04-13 AU AU2021257594A patent/AU2021257594B2/en active Active
-
2023
- 2023-11-27 JP JP2023199561A patent/JP2024028756A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP7316120B2 (ja) | 腫瘍性疾患のための治療 | |
| EP3076972B1 (en) | Cancer treatment with combination of plinabulin and taxane | |
| JP2024028756A5 (https=) | ||
| JP2015521607A (ja) | Ｇｄ２陽性癌を治療するための方法 | |
| JP2003504413A (ja) | 抗腫瘍物質を含む組み合わせ調製物 | |
| JP2021534094A5 (https=) | ||
| TWI817958B (zh) | 用於治療肝癌之組合物及方法 | |
| KR20220157515A (ko) | Liv1-adc와 화학요법제를 사용한 병용 요법 | |
| CN111246883A (zh) | 用抗pd-l1抗体和溶瘤病毒治疗三阴性乳癌或结肠直肠癌伴随肝转移 | |
| Razak et al. | A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: ARA Razak et al. | |
| CN112584861A (zh) | 使用组合疗法治疗癌症的方法 | |
| WO2025103377A1 (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| JPWO2020030977A5 (https=) | ||
| US20250019441A1 (en) | Treatment of cancer with anti-ilt2 antibodies | |
| WO2019129168A1 (zh) | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 | |
| Fattoruso et al. | Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer | |
| Muro et al. | P-95 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers | |
| WO2025245200A1 (en) | Ponsegromab for use in treating cachexia in cancer patients | |
| WO2025185682A1 (zh) | 含有抗egfr抗体或其片段的联合用药物 | |
| HK40122430A (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| WO2026046060A1 (zh) | 抗b7h3抗体药物偶联物用于治疗癌症的方法 | |
| WO2025159982A1 (en) | Treatment of non-small cell lung cancer using sacituzumab govitecan | |
| WO2026037393A1 (zh) | 一种抗体药物偶联物与酪氨酸激酶抑制剂的组合 | |
| CN119701004A (zh) | 抗her2抗体药物偶联物治疗妇科恶性肿瘤的方法和用途 |